The Translational Breast Cancer Research Consortium had two presentations at the 2017 ASCO Meeting. These included:

TBCRC 022 Phase II Trial of Neratinib + Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2+) Breast Cancer Brain Metastases (BCBM); Abstract #1005

TBCRC 036 Window of Opportunity Clinical Trial Reveals Adaptive Kinome Reprogramming in Single and Combination HER2-targeting in Breast Cancer; Abstract #1027